Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 26, 2026
Principal Business: Biotechnology company developing cell therapies, specifically Deramiocel for Duchenne muscular dystrophy (DMD).
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a regulatory event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No financial material changes are reported in this document. The primary event is the announcement of a scheduled FDA Advisory Committee meeting.
Outlook, Management Commentary, and Risks
- Regulatory Milestone: The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will convene on July 29, 2026, to discuss the Biologics License Application (BLA) for Deramiocel.
- Target Action Date: The BLA remains on track for a target Prescription Drug User Fee Act (PDUFA) action date of August 22, 2026.
- Event Details: The Advisory Committee meeting will be available for live streaming.
- Risks/Contingencies: The filing does not explicitly detail risks, though the outcome of the Advisory Committee meeting and the subsequent PDUFA decision are critical contingencies for the company's future.
Key Facts for Investor Verification
- Verify the date and agenda of the FDA Advisory Committee meeting scheduled for July 29, 2026.
- Confirm the status of the Deramiocel BLA and the August 22, 2026, PDUFA target action date.
- Review the attached press release (Exhibit 99.1) for additional details on the therapy and the meeting.
- Monitor subsequent filings for the outcome of the Advisory Committee meeting and the final FDA decision.